检索结果-南通市图书馆

Achieving high carrier mobility and low lattice thermal conductivity in GeTe-based alloys by cationic/anionic co-doping

在线全文

学校读者我要写书评

暂无评论

Rare Metals 2024年第6期43卷 2784-2795页

作者： xiao-qiang Wang xiao-Quan Hu jun-Yan lin Chu-bin li xiao-Tong yu Qi-Yong chen li-li xi Qi-Shuo Yang Han li Ji-Ye zhang Shuan-Kui li Kai guo School of Physics and Materials Science Guangzhou UniversityGuangzhou 510006China Research Center for Advanced Information Materials(CAIM) Huangpu Research&Graduate School of Guangzhou UniversitySino-Singapore Guangzhou Knowledge CityGuangzhou510555China School of Materials Science and Engineering Shanghai UniversityShanghai 200444China Materials Genome Institute Shanghai UniversityShanghai 200444China School of Mechanical and Mining Engineering University of QueenslandBrisbaneQLD 4072Australia Key Laboratory of Si-Based Information Materials&Devices and Integrated Circuits Design Department of Education of Guangdong ProvinceGuangzhou 510006China

TheⅣ-Ⅵcompound GeTe is considered as a promising alternative to the toxic PbTe for high-efficiency mid-temperature thermoelectric ***,pristine GeTe suffers from a high concentration of Ge vacancies,resulting in an excessively high hole concentration(>1×10^(21)cm^(-3)),which greatly limits its thermoelectric *** address this issue,CubiTe_(2)alloying is introduced to increase the formation energy of Ge vacancies in GeTe,thereby inhibiting the high carrier *** carrier scattering caused by the electronegativity difference between different elements is suppressed due to the similar electronegativity of Cu and Ge atoms.A relatively high hole mobility is obtained,which ultimately leads to a high power ***,by introducing Se as an alloying element at the anionic site in GeTe,dense point defects with mass/strainfield fluctuations are *** contributes to the strengthening of phonon scattering,thereby reducing the lattice thermal conductivity from 1.44 W·m^(-1)·K^(-1)for pristine GeTe to 0.28 W·m^(-1)·K^(-1)for Ge_(0.95)Cu_(0.05)bi_(0.05)Te_(0.9)Se_(0.15)compound at 623 K.

关键词： GeTe Carrier mobility CubiTe_(2)alloying Lattice thermal conductivity Thermoelectric properties

A practical community-based response strategy to interrupt Ebola transmission in sierra Leone, 2014–2015

在线全文

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2016年第1期5卷 670-679页

作者： Zhong-Jie li Wen-xiao Tu xiao-Chun Wang guo-Qing Shi Zun-Dong Yin Hai-jun Su Tao Shen Da-Peng zhang Jian-Dong li Shan Lv Chun-li Cao Rui-Qian xie Hong-Zhou Lu Rong-Meng Jiang zheng Cao Zhi-Jie An Lei-Lei li Jie Xu Yan-Wen xiong Wei Zang Wei zhang Hong-Wei zhang Wen-Sen chen Hua ling Wen Xu Jian Cai Huan-Jin Luo Xue-Sheng xing Can-jun zheng qiang Wei xin-Xu li Mei li Hai Jiang li-Quan Deng Ming-Quan chen xiang Huo Feng Xu Xue-Hui Lai xi-chen Bai Long-Jie Ye Jian-Yi Yao Wen-Wu Yin Jiao-Jin Sun lin xiao fu-qiang liu xiao-qiang liu Hong-Wei Fan Zeng-qiang Kou Ji-Kun Zhou Hao zhang Da-xin Ni Thomas TSamba Qun li Hong-Jie yu yu Wang xiao-Feng liang Division of Infectious Disease Key Laboratory of Surveillance and Early-warning on Infectious DiseaseChinese Center for Disease Control and PreventionBeijingChina Public Health Emergency Center Chinese Center for Disease Control and PreventionBeijingChina National Center for AIDS/STD Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Chinese Field Epidemiology Training Program Chinese Center for Disease Control and PreventionBeijingChina National Immunization Program Chinese Center for Disease Control and PreventionBeijingChina Bureau of Disease Prevention and Control National Health and Family Planning Commission of the People’s Republic of ChinaBeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina National Institute of Parasitic Disease Chinese Center for Disease Control and PreventionShanghaiChina Chinese Center for Health Education BeijingChina Department of Infectious Diseases Shanghai Public Health Clinical CenterShanghaiChina Beijing Ditan Hospital Capital Medical UniversityBeijingChina Health News BeijingChina National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Department of Training Chinese Center for Health EducationBeijingChina Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijingChina Infection Management The First Affiliated Hospital of Nanjing Medical UniversityNanjingChina Chongqing Municipal Center for Disease Control and Prevention ChongqingChina yunnan Provincial Center for Disease Control and Prevention KunmingChina Division of Infectious Disease Control and Prevention Zhejiang Provincial Center for Disease Control and PreventionHangzhouChina Guangdong Provincial Center for Disease Control and Prevention GuangzhouChina Division of Acute Infectious Disease Control and Prevention Hubei Provincial Center for Disease Control and PreventionW

Background:The Ebola virus disease spread rapidly in West Africa in 2014,leading to the loss of thousands of *** engagement was one of the key strategies to interrupt Ebola transmission,and practical community level measures needed to be explored in the field and tailored to the specific context of ***:First,community-level education on Ebola virus disease(EVD)prevention was launched for the community’s social mobilizers in six districts in Sierra Leone beginning in November ***,from January to May of 2015,in three pilot communities,local trained community members were organized to engage in implementation of EVD prevention and transmission interruption measures,by involving them in alert case report,contact tracing,and social *** epidemiological indicators of transmission interruption in three study communities were ***:A total of 6016 community social mobilizers from 185 wards were trained by holding 279 workshops in the six districts,and EVD message reached an estimated 631680 *** three pilot communities,72 EVD alert cases were reported,with 70.8%of them detected by trained local community members,and 14 EVD cases were finally *** tracing detected 64.3%of EVD *** median duration of community infectivity for the cases was 1 *** secondary attack rate was 4.2%,and no third generation of infection was *** health worker was infected,and no unsafe burial and noncompliance to EVD control measures were *** community-based measures were modeled to reduce 77 EVD cases,and the EVD-free goal was achieved four months earlier in study communities than whole country of Sierra ***: The community-based strategy of social mobilization and community engagement was effective in casedetection and reducing the extent of Ebola transmission in a country with weak health system. The successfullypractical experience to reduce the risk of Ebola transmission in the

关键词： Ebola virus disease Community engagement Health education Outbreak control

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： jun liu Dan-Dan li Wei Dong yu-Qi liu Yang Wu Da-Xuan Tang fu-Chun zhang Meng Qiu Qi Hua Jing-yu He jun li Bai Du Ting-Hai Du lin-lin Niu Xue-jun Jiang Bo Cui Jiang-bin chen Yang-Gan Wang Hai-Rong Wang Qin yu Jing He Yi-lin Mao xiao-Fang bin yue Deng yu-Dan Tian Qing-Hua Han Da-Jin liu li-Qin Duan Ming-jun Zhao Cui-Ying zhang Hai-Ying Dai Ze-Hua li Ying xiao You-Zhi Hu xiao-yu Huang Kun xing xin Jiang Chao-Feng liu Jing An Feng-Chun li Tao Tao Jin-Fa Jiang Ying Yang Yao-Rong Dong Lei zhang Guang fu Ying li Shu-Wei Huang li-Ping Dou Lan-jun Sun Ying-qiang Zhao Jie li yun xia jun liu Fan liu Wen-Jin He Ying li Jian-Cong Tan Yang lin Ya-bin Zhou Jian-Fei Yang guo-Qing Ma Hui-jun chen He-Ping liu Zong-Wu liu Jian-xiong liu xiao-Jia Luo xiao-Hong bin Ya-Nan yu Hai-xia Dang bing li Fei Teng Wang-Min Qiao xiao-Long Zhu bing-Wei chen Qi-Guang chen Chun-Ti Shen Yong-Yan Wang yun-Dai chen Zhong Wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated Zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

The Solar Upper Transition Region Imager(SUTRI)Onboard the SATech-01 Satellite

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2023年第6期23卷 153-171页

作者： xianyong Bai Hui Tian yuanyong Deng Zhanshan Wang Jianfeng Yang xiaofeng zhang Yonghe zhang Runze Qi Nange Wang Yang Gao jun yu Chunling He zhengxiang Shen Lun Shen Song guo Zhenyong Hou Kaifan Ji xingzi bi Wei Duan xiao Yang Jiaben lin Ziyao Hu Qian Song Zihao Yang Yajie chen Weidong Qiao Wei Ge fu li Lei Jin Jiawei He xiaobo chen xiaocheng Zhu junwang He Qi Shi liu liu Jinsong li Dongxiao Xu Rui liu Taijie li zhenggong Feng Yamin Wang chengcheng Fan Shuo liu Sifan guo zheng Sun yuchuan Wu Haiyu li Qi Yang yuyang Ye Weichen Gu Jiali Wu Zhe zhang yue yu Zeyi Ye Pengfeng Sheng Yifan Wang Wenbin li Qiushi Huang Zhong zhang National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China School of Astronomy and Space Science University of Chinese Academy of SciencesBeijing 101408China School of Earth and Space Sciences Peking UniversityBeijing 100871China Key Laboratory of Solar Activity and Space Weather National Space Science CenterChinese Academy of SciencesBeijing 100190China Tongji University Institute of Precision Optical EngineeringSchool of Physics Science and EngineeringKey Laboratory of Advanced Micro-Structured Materials MOEShanghaiChina xi'an Institute of Optics and Precision Mechanics Chinese Academy of SciencesXi'an 710119China Innovation Academy for Microsatellites Chinese Academy of SciencesShanghai 201304China yunnan Observatories Chinese Academy of SciencesKunming650011China

The Solar Upper Transition Region Imager(SUTRI)onboard the Space Advanced Technology demonstration satellite(SATech-01),which was launched to a Sun-synchronous orbit at a height of~500 km in 2022 July,aims to test the on-orbit performance of our newly developed Sc/Si multi-layer reflecting mirror and the 2k×2k EUV CMOS imaging camera and to take full-disk solar images at the Ne VII 46.5 nm spectral line with a filter width of~3 *** employs a Ritchey-Chrétien optical system with an aperture of 18 *** on-orbit observations show that SUTRI images have a field of view of~416×416 and a moderate spatial resolution of~8″without an image stabilization *** normal cadence of SUTRI images is 30 s and the solar observation time is about16 hr each day because the earth eclipse time accounts for about 1/3 of SATech-01's orbit ***15 GB data is acquired each day and made available online after *** images are valuable as the Ne VII 46.5 nm line is formed at a temperature regime of~0.5 MK in the solar atmosphere,which has rarely been sampled by existing solar *** observations will establish connections between structures in the lower solar atmosphere and corona,and advance our understanding of various types of solar activity such as flares,filament eruptions,coronal jets and coronal mass ejections.

关键词： Sun:transition region Sun:UV radiation Sun:activity space vehicles:instruments

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang yue-yi Deng Wei li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong guo jun Zhu Jing-ai Fang Xu-sheng liu li-hua Wang Rong Wang Nian-song Wang xiao-hong cheng li-qun He Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu chen Wen-hu liu Hong-li lin Meng liang Lu Ma Ming chen li-qun Song Jian chen Qing Zhu Chang-ying xing yun li Ji-ning Gao Rong-shan li Ying li Hao zhang Ying Lu Qiao-ling Zhou jun-zhou fu qiang He Guang-yan Cai xiang-mei chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

Frontiers in high entropy alloys and high entropy functional materials

在线全文

学校读者我要写书评

暂无评论

Rare Metals 2024年第10期43卷 4639-4776页

作者： Wen-Tao zhang Xue-Qian Wang Feng-Qi zhang xiao-Ya Cui bing-bing Fan Jia-Ming guo Zhi-Min guo Rui Huang Wen Huang Xu-Bo li Meng-Ru li Yan Ma Zhi-Hua Shen Yong-Gang Sun De-Zhuang Wang Fei-Yang Wang li-qiang Wang Nan Wang Tian-li Wang Wei Wang xiao-Yang Wang Yi-Han Wang fu-Jie yu yu-Zhen Yin ling-Kun zhang Yi zhang Jian-Yang zhang Qi Zhao yu-Ping Zhao xin-Dong Zhu Yasir Sohail Ya-Nan chen Tao Feng Qi-Long Gao Hai-Yan He Yong-Jiang Huang Zeng-Bao Jiao Hua Ji Yao Jiang qiang li xiao-Ming li Wei-bing liao Huai-jun lin Hui liu Qi liu Qing-Feng liu Wei-Di liu xiong-jun liu Yang Lu Yi-Ping Lu Wen Ma Xue-Fei Miao Jie Pan Qing Wang Hong-Hui Wu yuan Wu Tao Yang Wei-Ming Yang Qian yu Jin-yu zhang Zhi-Gang chen liang Mao Yang Ren Bao-Long Shen Xun-li Wang Zhe Jia He Zhu Zhen-Duo Wu Si Lan School of Materials Science and Engineering Nanjing University of Science and TechnologyNanjing 210094China Jiangsu Key Laboratory for Advanced Metallic Materials School of Materials Science and EngineeringSoutheast UniversityNanjing 211189China Department of Physics City University of Hong KongHongKong 999077China School of Materials Science and Engineering Tianjin UniversityTianjin 300072China School of Physics and Microelectronics Zhengzhou UniversityZhengzhou 450001China Department of Mechanical Engineering Research Institute for Advanced ManufacturingThe Hong Kong Polytechnic UniversityHong Kong 100872China Center of Electron Microscopy and State Key Laboratory of Silicon Materials School of Materials Science and EngineeringZhejiang UniversityHangzhou 310027China Key Laboratory of Solidification Control and Digital Preparation Technology(liaoning Province) School of Materials Science and EngineeringDalian University of TechnologyDalian 116024China Institute of Advanced Wear&Corrosion Resistance and functional Materials Jinan UniversityGuangzhou 510632China School of Mechanics and Civil Engineering China University of Mining and TechnologyXuzhou 221116China School of Physical Sciences Great Bay UniversityDongguan 523000China School of Materials Science and Engineering Harbin Institute of TechnologyHarbin 150001China State Key Laboratory of Materials-Oriented Chemical Engineering College of Chemical EngineeringNanjing Tech UniversityNanjing 211816China Beijing Advanced Innovation Center for Materials Genome Engineering Research Institute for Carbon NeutralityUniversity of Science and Technology BeijingBeijing 100083China Department of Mechanical Engineering The University of Hong KongHong Kong 999077China School of Computing Macquarie UniversitySydney 2113Australia Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province College of Physics and Optoelectronic EngineeringShenzhen UniversityShenzhen 518060China State Key Laborato

Owing to their exceptional properties,high-entropy alloys(HEAs)and high-entropy materials have emerged as promising research areas and shown diverse ***,the recent advances in the field are comprehensively reviewed,organized into five *** first section introduces the background of HEAs,covering their definition,significance,application prospects,basic properties,design principles,and *** subsequent section focuses on cutting-edge high-entropy structural materials,highlighting developments such as nanostructured alloys,grain boundary engineering,eutectic systems,cryogenic alloys,thin films,micro-nano-lattice structures,additive manufacturing,high entropy metallic glasses,nano-precipitate strengthened alloys,composition modulation,alloy fibers,and refractory *** the following section,the emphasis shifts to functional materials,exploring HEAs as catalysts,magneto-caloric materials,corrosion-resistant alloys,radiation-resistant alloys,hydrogen storage systems,and materials for ***,the review encompasses functional high-entropy materials outside the realm of alloys,including thermoelectric,quantum dots,nanooxide catalysts,energy storage materials,negative thermal expansion ceramics,and high-entropy wave absorption *** paper concludes with an outlook,discussing future directions and potential growth areas in the *** this comprehensive review,researchers,engineers,and scientists may gain valuable insights into the recent progress and opportunities for further exploration in the exciting domains of high-entropy alloys and functional materials.

关键词： High entropy alloys Cutting-edge structural materials Cutting-edgefunctional materials

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-bin ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku Jia li Zhuang Tian Shen li-Min Ding Zhi-Dan Xu Lai-Bang Luo li-Bo Sun Guang-Ming li Tai-Shi Fang Nan Jiang Kun zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang qiang He lin-Sen Ye Yang Yang yu-Ting He Wen-Zhi guo liu-Gen Lan Xu-Yong Sun Dong chen Zhi-Shui chen Da-Wei Zhou Shao-jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang lin Zhong Jing-Sheng Ma Qi-Gen li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua zhang Xuan Wang Zi-qiang li Mu-Jian Teng jun-Jie li Wen-Tao Jiang Jian-Hua li Quan-Bao zhang Ning-Qi Zhu zheng-xin Wang Kang He qiang xia Shao-Hua Song Zhi-Ren fu Wei Qiu guo-yue Lv Rui-Peng Song Ji-Zhou Wang zheng Wang Jian Zhou Gang chen Ying-Peng Zhao li li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si bin xie xiao-Shun He Zhi-Yong guo Shu-Sen zheng xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion

在线全文

学校读者我要写书评

暂无评论

biomarkers of aging

Science China(life Sciences) 2023年第5期66卷 893-1066页

作者： Aging biomarker Consortium Hainan Bao Jiani Cao Mengting chen Min chen Wei chen xiao chen Yanhao chen yu chen yutian chen Zhiyang chen Jagadish K Chhetri Yingjie Ding junlin Feng jun guo Mengmeng guo Chuting He yujuan Jia Haiping Jiang Ying Jing Dingfeng li Jiaming li Jingyi li Qinhao liang Rui liang Feng liu xiaoqian liu Zuojun liu Oscar junhong Luo Jianwei Lv Jingyi Ma Kehang Mao Jiawei Nie xinhua Qiao xinpei Sun xiaoqiang Tang Jianfang Wang Qiaoran Wang Siyuan Wang Xuan Wang Yaning Wang yuhan Wang Rimo Wu Kai xia fu-Hui xiao lingyan Xu Yingying Xu Haoteng Yan liang Yang Ruici Yang yuanxin Yang Yilin Ying Le zhang Weiwei zhang Wenwan zhang xing zhang Zhuo zhang Min Zhou Rui Zhou Qingchen Zhu zhengmao Zhu Feng Cao Zhongwei Cao Piu Chan Chang chen guobing chen Hou-Zao chen jun chen Weimin Ci bi-Sen Ding Qiurong Ding Feng Gao Jing-Dong JHan Kai Huang Zhenyu Ju Qing-Peng Kong Ji li Jian li xin li Baohua liu Feng liu lin liu qiang liu qiang liu xingguo liu Yong liu xianghang Luo Shuai Ma xinran Ma Zhiyong Mao Jing Nie Yaojin Peng Jing Qu Jie Ren Ruibao Ren Moshi Song Zhou Songyang Yi Eve Sun yu Sun Mei Tian Shusen Wang Si Wang xia Wang xiaoning Wang Yan-Jiang Wang yunfang Wang Catherine CL Wong Andy Peng xiang Yichuan xiao zhengwei xie Daichao Xu Jing Ye Rui yue Cuntai zhang Hongbo zhang liang zhang Weiqi zhang Yong zhang yun-Wu zhang Zhuohua zhang Tongbiao Zhao yuzheng Zhao Dahai Zhu Weiguo Zou Gang Pei Guang-Hui liu Aging biomarker Consortium(ABC) Beijing 100101China CAS Key Laboratory of Genomic and Precision Medicine Beijing Institute of GenomicsChinese Academy of Sciences and China National Center for BioinformationBeijing 100101China State Key Laboratory of Stem Cell and Reproductive biology Institute of ZoologyChinese Academy of SciencesBeijing 100101China Department of Dermatology Xiangya HospitalCentral South UniversityChangsha 410008China Hunan Key Laboratory of Aging biology Xiangya HospitalCentral South UniversityChangsha 410008China National Clinical Research Center for Geriatric Disorders Xiangya HospitalCentral South UniversityChangsha 410008China Clinic Center of Human Gene Research Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Hubei Clinical Research Center of Metabolic and Cardiovascular Disease Huazhong University of Science and TechnologyWuhan 430022China Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging Huazhong University of Science and TechnologyWuhan 430022China Stem Cell Translational Research Center Tongji HospitalTongji University School of MedicineShanghai 200065China Department of Nuclear Medicine Daping HospitalThird Military Medical UniversityChongqing 400042China CAS Key Laboratory of Nutrition Metabolism and Food SafetyShanghai Institute of Nutrition and HealthUniversity of Chinese Academy of SciencesChinese Academy of SciencesShanghai 200031China Shanghai Key Laboratory of Maternal Fetal Medicine Clinical and Translational Research Center of Shanghai First Maternity and Infant HospitalFrontier Science Center for Stem Cell ResearchShanghai Key Laboratory of Signaling and Disease ResearchSchool of Life Sciences and TechnologyTongji UniversityShanghai 200092China The Department of Endovascular Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Key Laboratory of Regenerative Medicine of Ministry of Education Institute of Ageing and Regenerative MedicineJ

Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological *** a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly *** immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this ***,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory *** fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant.

关键词： aging senescence biomarker clock

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-li Luo Yong-Heng Zhao Gang Zhao li-Cai Deng xiao-Wei liu Yi-Peng Jing Gang Wang Hao-Tong zhang Jian-Rong Shi xiang-Qun Cui Yao-Quan Chu guo-Ping li Zhong-Rui Bai yue Wu Yan Cai Shu-yun Cao Zi-Huang Cao Jeffrey L.Carlin Hai-yuan chen Jian-jun chen Kun-xin chen li chen Xue-Lei chen xiao-Yan chen Ying chen Norbert Christlieb Jia-Ru Chu chen-Zhou Cui Yi-Qiao Dong bing Du Dong-Wei Fan Lei Feng Jian-Ning fu Peng Gao Xue-Fei Gong Bo-Zhong Gu Yan-xin guo Zhan-Wen Han Bo-liang He Jin-liang Hou Yong-Hui Hou Wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu Zhi-Ying Huo Lei Jia Fang-Hua Jiang xiang Jiang Zhi-Bo Jiang Ge Jin xiao Kong Xu Kong Ya-Juan Lei Ai-Hua li Chang-Hua li Guang-Wei li Hai-Ning li Jian li Qi li Shuang li Sha-Sha li xin-Nan li Yan li Yin-bi li Ye-Ping li yuan liang Chien-cheng lin Chao liu Gen-Rong liu Guan-Qun liu Zhi-Gang liu Wen-Zhi Lu yu Luo Yin-Dun Mao Heidi Newberg Ji-jun Ni Zhao-xiang Qi Yong-jun Qi Shi-Yin Shen Huo-Ming Shi Jing Song Yi-Han Song Ding-qiang Su Hong-jun Su zheng-Hong Tang Qing-Sheng Tao yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang guo-Min Wang Hai Wang Hong-Chi Wang Jian Wang Jia-Ning Wang Jian-ling Wang Jian-Ping Wang jun-xian Wang Lei Wang Meng-xin Wang Shou-Guan Wang Shu-Qing Wang xia Wang Ya-Nan Wang You Wang yue-Fei Wang You-Fen Wang Peng Wei Ming-Zhi Wei Hong Wu Ke-Fei Wu Xue-bing Wu yu-Zhong Wu xiao-zheng xing ling-Zhe Xu xin-Qi Xu Yan Xu Tai-Sheng Yan De-Hua Yang Hai-Feng Yang Hui-Qin Yang Ming Yang zheng-Qiu Yao Yong yu Hui yuan Hai-Bo yuan Hai-Long yuan Wei-Min yuan Chao Zhai En-Peng zhang Hua-Wei zhang Jian-Nan zhang li-Pin zhang Wei zhang Yong zhang Yan-xia zhang zheng-Chao zhang Ming Zhao Fang Zhou Xu Zhou Jie Zhu Yong-Tian Zhu Si-cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in june 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in june 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog